Analyst Research Roundup: Teva Pharmaceutical Industries Limited (TEVA), BRF S.A. (BRFS)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) tinted gains of +0.33% (+0.05 points) to US$15.24. The volume of 7.47 Million shares climbed up over an trading activity of 10.55 Million shares. EPS ratio determined by looking at last 12 month figures is -2.23. Over the same time span, the stock marked US$25.96 as its best level and the lowest price reached was US$14.59. The corporation has a market cap of US$16.47 Billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s earnings per share has been growing at a -28.5 percent rate over the past 5 year when average revenue increase was noted as -1.5 percent. The return on equity ratio or ROE stands at -16.6 percent while most common profitability ratio return on investment (ROI) was -3.2 percent. The company’s institutional ownership is monitored at 64 percent. The company’s net profit margin has achieved the current level of -12.7 percent and possesses 44 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 18 think it is Hold. Recently, analysts have updated the overall rating to 2.76. 2 analysts recommended Overweight these shares while 2 recommended Underweight, according to FactSet data.

BRF S.A. (NYSE:BRFS) is worth US$4.99 Billion and has recently risen 0.33% to US$6.17. The latest exchange of 3.62 Million shares is below its average trading activity of 3.81 Million shares. The day began at US$6.17 but the price moved to US$6.17 at one point during the trading and finally capitulating to a session high of US$6.27. The stock tapped a 52-week high of US$7.64 while the mean 12-month price target for the shares is US$6.87.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 2.8, and a price to sales ratio of 0.64. For the past 5 years, the company’s revenue has grown 1.7%, while the company’s earnings per share has grown -33.4%. With an institutional ownership near 11.3%, it carries an earnings per share ratio of -0.66.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 1 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.57.